OptiBiotix partners with Select Ingredient to bring its patented probiotic strain LPLDL to the US and Canadian markets
OptiBiotix Health PLC (‘OptiBiotix’), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, has announced a new distribution deal with Advanced NutriSolutions Inc, trading as Select Ingredient, to deliver its cholesterol and blood-pressure reducing probiotic strain LPLDL to the US and Canadian markets.
The exclusive contract between ProBiotix Health, a wholly owned subsidiary of OptiBiotix, and Select Ingredient will enable the inclusion of LPLDL into dietary supplements to help combat cardiovascular disease, lower harmful cholesterol levels and reduce blood pressure
With almost 650,000 deaths in the US[1], heart disease is seen as one of the leading causes of death in the region. Science-backed innovations like LPLDL have shown efficacy through controlled human studies, reducing overall cholesterol levels by up to 36.7% and systolic blood pressure by up to 5.1%, helping to improve heart health and physiological wellbeing.
Steve Prescott, CEO of ProBiotix Health, commented: “Select Ingredient is a partner of choice in the US and Canadian markets, primarily due to the company’s technical expertise in functional ingredients and industry reputation. In addition, its on-site manufacturing capabilities mean LPLDL can be sold as both an ingredient into dietary supplements and as a custom formulation for new customers.”
Founded in 1994, Select Ingredient supplies nutritional ingredients, contract manufacturing services and finished products to the nutritional supplement industry. The company’s headquarters are in San Diego, California.
[1] Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–528.